Teladoc Health, Inc 8-K/A, filed Nov 20, 2020
Teladoc Health, Inc. (TDOC)
About this 8-K/A
Teladoc Health, Inc filed this 8-K/A on November 20, 2020, reporting on events of October 30, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Amendment No. 1
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory Note
On October 30, 2020, Teladoc Health, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) under Item 5.02 to report the appointment of Chris Bischoff, Karen L. Daniel, Sandra Fenwick, Hemant Taneja and Glen Tullman to the Company’s Board of Directors (the “Board”), effective as of November 19, 2020. At the time of the Original Form 8-K filing, the Board had not yet determined on which committees each of Mr. Bischoff, Ms. Daniel, Ms. Fenwick, Mr. Taneja and Mr. Tullman would serve. The Company is filing this Amendment No. 1 to the Original Form 8-K to disclose the subsequent appointment of Mr. Bischoff, Ms. Daniel, Ms. Fenwick, Mr. Taneja and Mr. Tullman to Board committees. No other changes have been made to the Original Form 8-K.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of November 19, 2020, Mr. Bischoff has been appointed to the Audit Committee and the Compensation Committee of the Board, Ms. Daniel has been appointed to the Audit Committee of the Board, Ms. Fenwick has been appointed to the Nominating and Corporate Governance Committee and the Quality of Care and Patient Safety Committee of the Board, Mr. Taneja has been appointed as Chairman of the newly formed Technology Committee of the Board, and Mr. Tullman has been appointed to the Technology Committee of the Board.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 20, 2020 | TELADOC HEALTH, INC. | ||||
| By: | /s/ Adam C. Vandervoort | ||||
| Name: | Adam C. Vandervoort | ||||
| Title: | Chief Legal Officer | ||||